Matrix metalloproteinase-1 expression can be upregulated through mitogen-activated protein kinase pathway under the influence of human epidermal growth factor receptor 2 synergized with estrogen receptor

Molecular Cancer Research

Volumn 8, Issue 7, 2010, Pages 1037-1047

  Jung, Hae Hyun ^a   Park, Yeon Hee ^a   Jun, Hyun Jung ^a   Kong, Jeehyun ^a   Kim, Jeong Hoon ^a   Kim, Jung A ^a   Yun, Jina ^a   Sun, Jong Mu ^a   Won, Young Woong ^a   Lee, Soohyeon ^a   Kim, Seung Tae ^a   Ahn, Jin Seok ^a   Im, Young Hyuck ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR;

ARTICLE; CELL STRAIN MCF 7; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; GENETIC TRANSFECTION; GENETICS; METABOLISM; TUMOR CELL LINE;

CELL LINE, TUMOR; HUMANS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 1; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION;

EID: 77955459810     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0469     Document Type: Article

References (38)

1. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003;9:447-54S.
2. Johnston SR. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin Cancer Res 2005;11:889-99s.
3. Arpino G, Wiechmann L, Osborne K, et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy. Endocrine Rev 2008;29:217-33.
4. Gutierrez MC, Detre S, Johnston S, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005;23:2469-76.
5. Wang Q, Greene MI. Mechanisms of resistance to ErbB-targeted cancer therapeutics. J Clin Invest 2008;118:2389-92.
6. Fogarty MP, Kessler JD, Wechsler-Reya RJ. Morphing into cancer: the role of developmental signaling pathways in brain tumor formation. J Neurobiol 2005;64:458-75.
7. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
8. Marchio C, Natrajan R, Shiu KK, et al. The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 2008; 216:399-407.
9. DeNardo DG, Kim HT, Hilsenbeck S, et al. Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: Identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrinol 2005;19:362-78.
10. Safe S, Kim K. Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol 2008;41:263-75.
11. Osborne CK, Schiff R, Fuqua SA, et al. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001;7:4338-42s.
12. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005;23:1616-22.
13. Park YH, Jung HH, Ahn JS, et al. Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells. Biochem Biophys Res Commun 2008;377:389-94.
14. Mizumoto H, Saito T, Ashihara K, et al. Acceleration of invasive activity via matrix metalloproteinases by transfection of the estrogen receptor-α gene in endometrial carcinoma cells. Int J Cancer 2002; 100:401-6.
15. Lu T, Yamini A, Sciore P, et al. Estrogen receptor α regulates matrix metalloproteinase-13 promoter activity primarily through the AP-1 transcriptional regulatory site. Biochim Biophys Acta 2006;1762: 719-31.
16. Zhou Y, Yau C, Gray JW, et al. Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007;7:59.
17. Gutman A, Wasylyk B. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. EMBO J 1990;9:2241-6.
18. Tovey SM, Reeves JR, Stanton P, et al. Low expression of HER2 protein in breast cancer is biologically significant. J Pathol 2006; 210:358-62.
19. Zhu Y, Sullivan LL, Nair SS, et al. Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res 2006;66:7991-8.
20. Fagan DH, Yee D. Crosstalk between IGF 1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008; 13:423-9.
21. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (Protein Kinase B). Science 1999;286:1741-4.
22. Kaufman B. Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2 positive, hormone-dependent metastatic breast cancer (MBC). European Society of Medical Oncology (ESMO) Congress 2006. [abstract #LBA2].
23. Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007;102:43-9.
24. Katzenellenbogen BS, Frasor J. Therapeutic targeting in the estrogen receptor hormonal pathway. Semin Oncol 2004;31:28-38.
25. Green KA, Carroll JS. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer 2007;7:713-22.
26. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tributions. Science 2002;295: 2387-92.
27. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657-72.
28. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003;22:177-203. (Pubitemid 36561057)
29. Benhow U, Brinckerhoff CE. The AP-1 site and MMP gene regulation: What is all the fuss about? Matrix Biol 1997;15:519-26.
30. Ozanne BW, Spence HJ, McGarry LC, et al. Transcription factors control invasion: AP-1 the first among equals. Oncogene 2007;26:1-10.
31. Bedard PL, Freedman OC, Howell A, et al. Overcoming endocrine resistance in breast cancer-are signal transduction inhibitors the answer? Breast Cancer Res Treat 2008;108:307-17.
32. Yang Z, Barnes CJ, Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor α in breast cancer cells. Clin Cancer Res 2004;10: 3621-8.
33. Demers LM. Bone markers in the management of patients with skeletal metastases. Cancer 2003;97:874-9.
34. Hayami T, Kapila YL, Kapila S. MMP-1 (collagenase-1) and MMP-13 (collagenase-3) differentially regulate markers of osteoblastic differentiation in osteogenic cells. Matrix Biol 2008;27:682-92.
35. McGowan PM, Duffy MJ. Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol 2008;19:1566-72.
36. Eck SM, Hoopes PJ, Petrella BL, et al. Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat 2009;116:79-90.
37. Esteva FJ, Valero V, Pusztai L, et al. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001;6:133-46.
38. Carmichael AR, Anderson ED, Chetty U, et al. Does local surgery have a role in the management of stage IV breast cancer? Eur J Surg Oncol 2003;29:17-9.